While this trial - s primary efficacy goals are to evaluate anti-tumor activity in PD -
L1 positive tumors, preliminary exploration of antitumor activity will also be conducted in a subset of PD - L1 negative tumors based upon response observed in PD -
L1 positive tumors or lymphoma in this trial.
Provide example data from experiments using PD -
L1 positive tumors and a cancer cell - line engraftment into a humanized mouse model that was used to test anti-PD1 immune therapy
Not exact matches
Patients in the trial had advanced NSCLC, and their
tumors tested
positive for PD -
L1 levels of 50 % or more.
«Interestingly, we found that activity of pembrolizumab was seen in both PD -
L1 -
positive and - negative
tumors.
The trial investigated the drug in two separate cohorts of patients: Cohort A, which included 170 patients with heavily pretreated metastatic triple negative breast cancer (mTNBC) regardless of PD -
L1 expression, and Cohort B, which included 52 patients with PD -
L1 -
positive tumors who received it as first - line therapy.
A Phase I / II Study of Pembrolizumab (MK - 3475) in Children with Advanced Melanoma or a PD -
L1 Positive Advanced, Relapsed or Refractory Solid
Tumor or Lymphoma